CSIMarket
 
Avrobio Inc   (AVRO)
Other Ticker:  
 
 
Price: $1.3000 $0.03 2.362%
Day's High: $1.305 Week Perf: 0.00
Day's Low: $ 1.20 30 Day Perf: 0.78 %
Volume (M): 494 52 Wk High: $ 1.70
Volume (M$): $ 642 52 Wk Avg: $1.28
Open: $1.25 52 Wk Low: $0.57



 Market Capitalization (Millions $) 58
 Shares Outstanding (Millions) 45
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) -84
 Capital Exp. (TTM) (Millions $) 0

Avrobio Inc
Avrobio Inc is a clinical-stage gene therapy company that specializes in the development of transformative ex vivo lentiviral gene therapies to treat a range of rare genetic diseases. The company's approach involves taking a patient's own cells, modifying them with a lentivirus to insert a functional gene, and then re-infusing these modified cells back into the patient's body.

Avrobio's gene therapies aim to address the root cause of genetic diseases by providing long-lasting and potentially curative treatments. They focus on inherited, lysosomal storage disorders such as Fabry disease, Gaucher disease, and cystinosis, among others. These disorders result from the defective functioning of specific enzymes, leading to the accumulation of toxic substances in cells throughout the body.

The company's lead candidate, AVR-RD-01, is being studied for the treatment of Fabry disease, an inherited disorder that leads to the accumulation of fatty substances in various organs. Avrobio is also actively advancing other programs in its pipeline.

Avrobio utilizes a clinical-stage gene therapy platform called plato', which includes proprietary vectorization and drug product technologies. The company aims to optimize and streamline the manufacturing process of gene therapies to make them more accessible and affordable for patients.

By focusing on rare diseases with high unmet medical need, Avrobio aims to provide innovative solutions that offer transformative outcomes for affected individuals and their families.


   Company Address: 100 Technology Square Cambridge 2139 MA
   Company Phone Number: 914-8420   Stock Exchange / Ticker: NASDAQ AVRO
   AVRO is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Avrobio Inc

Avrobio Inc. Witnesses Encouraging Progress as Operating Shortfall Narrows to $-22.985 Million in Q3 of 2023 Fiscal Year

Avrobio Inc: A Promising Future Ahead
During the recent earnings cycle, many businesses in the Biotechnology & Pharmaceuticals sector have reported their numbers, and Avrobio Inc is among them. The company recently declared an operating shortfall of $-22.933 million for the most recent fiscal period, which is undoubtedly a significant amount. However, it is important to note that this operating shortfall is actually an improvement compared to the same quarter in the previous year, where the losses were at $-22.969 million.
Avrobio Inc primarily focuses on expansion, and it is evident that their recent course of action on the operating level has overshadowed the same category in the similar time-frame a year prior. This is a positive development as it shows that the company is making progress towards its goals. The reduction in losses to $-21.577 million from $-22.969 million in the third quarter of 2022 is a step in the right direction. This improvement may aid Avrobio Inc in establishing itself as a major player in the industry.

Avrobio Inc

Avrobio Inc Surprises Investors with Jaw-Dropping $68 Million Surplus, Defying Expectations of Revenue-Free Quarter

Exciting Developments in the Biotechnology & Pharmaceuticals Sector
The stock market is alive with anticipation as the Biotechnology & Pharmaceuticals sector researchers dive into the analysis of second quarter earnings for 2023. Among the companies under scrutiny is Avrobio Inc, whose financial results have left investors amazed and delighted.
Avrobio Inc recently reported a remarkable operating surplus of $68.007 million for the period between April and June 2023. What sets this achievement apart is the fact that the company didn't mention any revenue during this time frame. Clearly, the strategies implemented in managing day-to-day operations have overshadowed those of the previous year, leading to this impressive surplus.

Avrobio Inc

1. Revised headline: Avrobio Inc Sustains Genuine Growth in First Quarter of 2023 Financial Report Despite Operating Shortfall of $-25.22 Million2. Subtitle: Challenges on the Road to Profitability: Avrobio Inc Faces Revenue Adjustments and Financial Stability Risks amidst Decrease in Operating Shortfall

Avrobio Inc faces challenges in the road to profitability as the company reported a considerable operating shortfall of $-25.22 million in the first quarter of fiscal January to March 31 2023. Although this amount represents a decrease when compared to the $-29.418 million shortfall from the same period in 2022, the company's shareholders have not assumed some adjustments at the revenue, risking the financial stability of the corporation.
The AVRO's shortfall numbers are an essential reflection of the state of the company, and while ascending entities like AVRO build up their revenue sources, it is crucial for those companies to operate efficiently to achieve the next phase. The company appears to be still emerging the revenue sources that will allow it to break even, and this implies that measures and adjustments need to be made to control the financial shortfall.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com